Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00676403 · ClinicalTrials.gov registry record · Phase 2
Lyrica Dose Response Study With Restless Legs Syndrome (RLS) Patients
A Phase 2 study, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris.
- Completed
- Registry status
- Phase 2
- Development phase
- 137
- Enrollment target
NCT00676403 is a Phase 2 study that has completed, run by Pfizer's Upjohn has merged with Mylan to form Viatris. The registered enrollment target is 137 participants.
The verdict
NCT00676403, a Phase 2 study, has completed, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 137 participants
- Enrollment target
Study Summary
To test the effectiveness and tolerability of Lyrica at various dose levels in RLS patients
Interventions
- DRUG placebo
- DRUG Pregabalin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 137 participants |
| Start Date | 2008-04 |
| Est. Completion | 2009-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00676403
The ClinicalTrials.gov registry entry for NCT00676403 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 137 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer's Upjohn has merged with Mylan to form Viatris, which has 158 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT00676403 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00676403 about?
NCT00676403 is a clinical study titled "Lyrica Dose Response Study With Restless Legs Syndrome (RLS) Patients". To test the effectiveness and tolerability of Lyrica at various dose levels in RLS patients
What is the current status of trial NCT00676403?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 137 participants. The study started on 2008-04. Estimated completion is 2009-01.
What interventions are being tested in trial NCT00676403?
The interventions under investigation include: placebo (DRUG), Pregabalin (DRUG).
Who is sponsoring clinical trial NCT00676403?
This trial is sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris, which has 158 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.